StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
29
This year
4
Publishing Date
2024 - 03 - 04
1
2024 - 01 - 29
1
2024 - 01 - 16
1
2024 - 01 - 04
1
2023 - 11 - 28
1
2023 - 11 - 27
1
2023 - 11 - 09
1
2023 - 11 - 06
1
2023 - 10 - 19
1
2023 - 10 - 16
1
2023 - 08 - 08
1
2023 - 07 - 11
1
2023 - 04 - 17
1
2023 - 03 - 30
1
2023 - 02 - 27
1
2023 - 02 - 21
1
2023 - 01 - 05
1
2022 - 12 - 20
1
2022 - 10 - 24
1
2022 - 08 - 08
1
2022 - 08 - 04
1
2022 - 07 - 12
1
2022 - 05 - 09
1
2022 - 04 - 04
1
2022 - 02 - 28
1
2022 - 02 - 23
1
2022 - 01 - 06
1
2021 - 11 - 10
1
2021 - 10 - 28
1
Sector
Consumer non-durables
29
Health technology
29
Manufacturing
29
Tags
Agreement
2
Application
3
Biopharma
2
Biotech-bay
9
Business
2
Candidate
1
Clearance
3
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
1
Collaboration
1
Commercial
1
Control
1
Designation
1
Disease
11
Drug
3
Fda
4
Fda clearance
1
Fda-approvals
1
Financial
3
Financial results
2
Global
1
Grant
1
Granted
1
Jones
1
N/a
17
New drug
1
Ongoing
2
Phase 1
3
Phase 2
4
Pneumococcal
14
Positive
3
Potential
1
Report
1
Results
7
Study
8
Therapy
1
Topline
1
Update
5
Vaccine
4
Vax-24
11
Vax-31
3
Year
1
Entities
Abb ltd
5
Abbott laboratories
4
Accenture plc
5
Akouos, inc.
3
Alcon inc.
5
Alibaba group holding ltd
7
Aon plc
3
Arrival
9
Asos plc
10
Astronics corp
3
Athira pharma, inc.
7
Blackrock, inc.
3
Bnp paribas
3
Bp plc
3
Cbl international ltd
10
China life insurance co ltd
3
Clean energy fuels corp.
8
Coty inc.
8
Denso corp
3
Digital ally, inc.
28
Eli lilly and company
6
Endeavour silver corporation
5
Equinor asa
7
Excelerate energy, inc.
4
Exxon mobil corporation
3
Fluent, inc.
3
Global partners lp
4
Hanesbrands inc.
4
Hepion pharmaceuticals, inc.
4
Honeywell international inc.
3
Hubspot, inc.
3
Johnson & johnson
7
Kering
1131
Levi strauss & co
5
Li ning co. ltd.
5
Linde plc
4
Lvmh moet hennessy louis vuitton
69
Methanex corporation
4
Mondelez international, inc.
3
Morgan stanley
8
Movado group inc.
4
Navigator holdings ltd.
6
Nextech ar solutions corp.
4
Oasis petroleum inc
4
Orange
20
Perella weinberg partners - class a
5
Pvh corp.
36
Qualcomm incorporated
4
Ralph lauren corporation
5
Royal dutch shell plc
14
S&p global inc.
8
Sanofi
6
Seacor marine holdings inc.
3
Sempra energy
4
Snowflake inc.
3
Sutro biopharma, inc.
29
Tencent holdings ltd
4
Totalenergies se
10
Upay
24
Vaxcyte, inc.
32
Symbols
ABBV
1
ABT
1
ADCT
1
ADVM
1
ALPMF
2
ALPMY
2
AZN
2
BIIB
1
BX
1
CLLS
1
DHR
1
EXEL
1
FMTX
1
GILD
1
GTHX
1
IMAX
1
IMGN
2
INCY
1
IOBT
1
JNJ
1
NKTR
2
PCVX
76
PPRUF
29
PPRUY
29
PTN
2
SNY
4
SNYNF
2
SRNE
1
STRO
270
TAK
1
VIR
1
VXRT
1
ZYME
1
Exchanges
Nasdaq
29
Nyse
1
Crawled Date
2024 - 03 - 04
1
2024 - 01 - 29
1
2024 - 01 - 16
1
2024 - 01 - 04
1
2023 - 11 - 28
1
2023 - 11 - 27
1
2023 - 11 - 09
1
2023 - 11 - 06
1
2023 - 10 - 19
1
2023 - 10 - 16
1
2023 - 08 - 08
1
2023 - 07 - 11
1
2023 - 04 - 17
1
2023 - 03 - 30
1
2023 - 02 - 28
1
2023 - 02 - 21
1
2023 - 01 - 05
1
2022 - 12 - 20
1
2022 - 10 - 24
1
2022 - 08 - 08
1
2022 - 08 - 04
1
2022 - 07 - 12
1
2022 - 05 - 09
1
2022 - 04 - 04
1
2022 - 02 - 28
1
2022 - 02 - 23
1
2022 - 01 - 06
1
2021 - 11 - 10
1
2021 - 10 - 28
1
Crawled Time
01:00
1
11:00
2
12:00
1
12:20
1
12:30
1
13:00
2
13:30
3
14:00
2
15:00
3
17:00
1
20:00
1
21:00
6
22:00
3
23:00
2
Source
www.biospace.com
12
www.globenewswire.com
16
www.sutrobio.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Sutro biopharma, inc.
symbols :
Ppruf
save search
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Published:
2024-03-04
(Crawled : 13:30)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-21.28%
|
O:
-0.59%
H:
0.27%
C:
-1.83%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-19.77%
|
O:
-1.85%
H:
0.2%
C:
-0.07%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
-14.1%
|
O:
0.2%
H:
0.18%
C:
-0.42%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-23.84%
|
O:
0.2%
H:
1.81%
C:
-3.43%
vax-24
disease
pneumococcal
study
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published:
2024-01-29
(Crawled : 13:30)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-12.22%
|
O:
0.92%
H:
0.76%
C:
-1.38%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-11.22%
|
O:
-0.55%
H:
1.4%
C:
1.28%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
-4.21%
|
O:
0.26%
H:
6.59%
C:
6.23%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-19.79%
|
O:
-0.43%
H:
6.84%
C:
6.62%
vax-31
disease
pneumococcal
study
Vaxcyte Appoints Whitney Jones as Chief People Officer
Published:
2024-01-16
(Crawled : 21:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-7.13%
|
O:
-2.87%
H:
0.1%
C:
-0.62%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-4.84%
|
O:
-3.45%
H:
0.61%
C:
0.53%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
-0.24%
|
O:
-1.81%
H:
3.73%
C:
3.69%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-2.58%
|
O:
-2.07%
H:
8.71%
C:
8.44%
jones
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
Published:
2024-01-04
(Crawled : 21:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-13.64%
|
O:
-1.72%
H:
1.77%
C:
-1.05%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-10.83%
|
O:
-1.13%
H:
1.81%
C:
0.95%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
-4.26%
|
O:
-2.53%
H:
0.56%
C:
-4.66%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-15.09%
|
O:
-4.28%
H:
0.0%
C:
-17.88%
pneumococcal
vaccine
update
potential
Vaxcyte Appoints Jacks Lee to Board of Directors
Published:
2023-11-28
(Crawled : 14:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-17.98%
|
O:
-1.83%
H:
1.83%
C:
-2.33%
SNYNF
|
News
|
$92.7
600K
|
Health Technology
|
-2.28%
|
O:
-1.89%
H:
0.02%
C:
0.02%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-16.44%
|
O:
-2.83%
H:
1.05%
C:
0.51%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
22.88%
|
O:
-1.82%
H:
1.91%
C:
1.75%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
65.35%
|
O:
6.14%
H:
1.24%
C:
-5.79%
SNY
|
News
|
$47.72
1.21%
1.1M
|
Health Technology
|
-2.89%
|
O:
-1.41%
H:
0.87%
C:
0.0%
GTHX
|
$4.255
3.78%
240K
|
Health Technology
|
150.0%
|
O:
-0.61%
H:
4.91%
C:
3.68%
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
Published:
2023-11-27
(Crawled : 21:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-17.98%
|
O:
-1.83%
H:
1.83%
C:
-2.33%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-16.44%
|
O:
-2.83%
H:
1.05%
C:
0.51%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
22.88%
|
O:
-1.82%
H:
1.91%
C:
1.75%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
65.35%
|
O:
6.14%
H:
1.24%
C:
-5.79%
vaccine
control
biopharma
agreement
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published:
2023-11-09
(Crawled : 13:30)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-16.3%
|
O:
-1.41%
H:
1.77%
C:
-1.32%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-14.19%
|
O:
1.28%
H:
0.21%
C:
-1.4%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
21.74%
|
O:
0.59%
H:
0.63%
C:
-5.62%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
55.14%
|
O:
4.12%
H:
0.0%
C:
-11.07%
vax-31
disease
pneumococcal
study
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
Published:
2023-11-06
(Crawled : 21:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-13.28%
|
O:
4.04%
H:
0.01%
C:
-0.94%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-13.42%
|
O:
-0.66%
H:
1.13%
C:
0.77%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
27.67%
|
O:
-0.52%
H:
7.4%
C:
4.69%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
40.67%
|
O:
1.49%
H:
0.74%
C:
-3.68%
business
update
financial
results
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published:
2023-10-19
(Crawled : 12:30)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-16.88%
|
O:
-0.57%
H:
1.09%
C:
0.98%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-13.69%
|
O:
1.4%
H:
0.53%
C:
-0.81%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
33.83%
|
O:
0.24%
H:
2.54%
C:
0.78%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
7.1%
|
O:
-0.28%
H:
0.0%
C:
-6.27%
vax-31
fda
drug
disease
pneumococcal
clearance
application
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
Published:
2023-10-16
(Crawled : 12:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-13.06%
|
O:
1.46%
H:
2.75%
C:
2.06%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-13.04%
|
O:
0.61%
H:
1.43%
C:
1.31%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
33.91%
|
O:
0.8%
H:
2.8%
C:
1.1%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-4.31%
|
O:
1.52%
H:
0.25%
C:
-7.25%
pneumococcal
global
collaboration
commercial
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
Published:
2023-08-08
(Crawled : 20:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-34.6%
|
O:
1.36%
H:
3.13%
C:
2.6%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-34.98%
|
O:
0.62%
H:
0.32%
C:
-0.47%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
26.05%
|
O:
-1.78%
H:
2.91%
C:
-2.19%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-8.5%
|
O:
0.0%
H:
2.91%
C:
2.43%
business
update
financial
results
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published:
2023-07-11
(Crawled : 12:20)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-31.0%
|
O:
3.26%
H:
0.0%
C:
-0.57%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-30.28%
|
O:
1.02%
H:
0.9%
C:
0.75%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
29.38%
|
O:
-2.77%
H:
2.2%
C:
0.65%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-20.63%
|
O:
-1.47%
H:
1.71%
C:
0.64%
vax-24
disease
pneumococcal
ongoing
study
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Published:
2023-04-17
(Crawled : 11:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-41.57%
|
O:
0.05%
H:
1.69%
C:
-1.81%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-41.75%
|
O:
-2.08%
H:
0.03%
C:
-0.19%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
68.77%
|
O:
15.18%
H:
6.42%
C:
0.71%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-14.32%
|
O:
0.68%
H:
8.13%
C:
5.64%
vax-24
pneumococcal
vaccine
positive
study
phase 2
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published:
2023-03-30
(Crawled : 15:00)
- biospace.com/
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-41.87%
|
O:
2.52%
H:
2.74%
C:
2.74%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-41.73%
|
O:
1.88%
H:
1.04%
C:
0.57%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
67.16%
|
O:
-0.52%
H:
0.55%
C:
-1.06%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-20.96%
|
O:
-1.05%
H:
2.86%
C:
-5.08%
vax-24
disease
pneumococcal
study
phase 2
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published:
2023-02-27
(Crawled : 01:00)
- globenewswire.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-39.45%
|
O:
-2.33%
H:
1.29%
C:
0.07%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-37.96%
|
O:
-1.23%
H:
0.49%
C:
-0.14%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
45.63%
|
O:
-5.44%
H:
2.81%
C:
2.42%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-34.21%
|
O:
0.0%
H:
5.06%
C:
-1.57%
year
financial
update
results
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
Published:
2023-02-21
(Crawled : 14:00)
- biospace.com/
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-42.92%
|
O:
-3.64%
H:
3.09%
C:
1.33%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-41.73%
|
O:
-1.68%
H:
1.12%
C:
-0.58%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
39.3%
|
O:
-0.93%
H:
1.96%
C:
0.55%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-39.39%
|
O:
-1.13%
H:
5.37%
C:
-0.98%
vax-24
fda
clearance
drug
disease
application
pneumococcal
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
Published:
2023-01-05
(Crawled : 15:00)
- biospace.com/
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-31.74%
|
O:
1.3%
H:
2.07%
C:
1.45%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-31.82%
|
O:
0.44%
H:
0.55%
C:
-0.17%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
31.46%
|
O:
-0.13%
H:
0.45%
C:
-1.58%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-53.46%
|
O:
-0.86%
H:
7.35%
C:
5.23%
vax-24
fda
designation
disease
granted
therapy
pneumococcal
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
Published:
2022-12-20
(Crawled : 22:00)
- sutrobio.com
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-26.97%
|
O:
2.83%
H:
2.66%
C:
-0.36%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-25.53%
|
O:
1.46%
H:
1.58%
C:
0.82%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
37.07%
|
O:
0.22%
H:
3.45%
C:
3.2%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-43.56%
|
O:
4.79%
H:
1.43%
C:
0.0%
biopharma
grant
agreement
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published:
2022-10-24
(Crawled : 11:00)
- biospace.com/
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-17.99%
|
O:
0.55%
H:
3.41%
C:
-0.9%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-18.21%
|
O:
-0.01%
H:
0.83%
C:
-0.01%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
199.32%
|
O:
70.8%
H:
2.7%
C:
-6.12%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-33.16%
|
O:
0.71%
H:
14.96%
C:
13.91%
candidate
disease
topline
vaccine
positive
study
pneumococcal
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
Published:
2022-08-08
(Crawled : 22:00)
- biospace.com/
PPRUF
|
News
|
$364.27
850
|
Consumer Non-Durables
|
-32.99%
|
O:
5.95%
H:
0.0%
C:
-1.24%
PPRUY
|
News
|
$36.96
220K
|
Manufacturing
|
-33.33%
|
O:
1.46%
H:
0.62%
C:
-0.53%
PCVX
|
$61.56
-0.07%
350K
|
Health Technology
|
137.56%
|
O:
0.62%
H:
0.13%
C:
-0.65%
STRO
|
$3.815
1.19%
410K
|
Health Technology
|
-34.55%
|
O:
0.69%
H:
10.52%
C:
6.72%
update
results
← Previous
1
2
Next →
Gainers vs Losers
87%
13%
Top 10 Gainers
MTTR
|
News
M
|
$4.56
162.07%
21M
|
AGBA
|
$2.74
119.2%
52M
|
Finance
CZOO
|
$9.07
81.76%
22M
|
EDBL
|
News
|
$6.56
74.47%
1.8M
|
MTC
|
$2.21
41.67%
5.6M
|
Technology Services
OPRT
|
News
|
$3.12
38.67%
11M
|
Finance
PALI
|
$6.59
33.67%
23M
|
Manufacturing
VNRX
|
$0.7945
32.42%
3.1M
|
Health Technology
MLEC
|
$1.81
29.29%
2.8M
|
n/a
BTCM
|
$3.45
27.78%
640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.